Anemia Clinical Trials

Find Anemia Clinical Trials Near You

Integrating Point of Care Testing (POCT) For Newborn Screening and Early Care for Sickle Cell Disease in Yopougon, Côte d'Ivoire

Status: Recruiting
Intervention Type: Combination product
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

The goal of this clinical trial is to learn if a multifaceted intervention composed of Gazelle-Multispectral sickle cell disease (SCD) point of care testing (POCT) and early initiation of comprehensive SCD care in children with SCD disease aged 0 - 6 months can improve their clinical outcomes. The main questions it aims to answer are: * Does the intervention lower the number of SCD-related illnesses? * Does the intervention lower the illness incidence defined as seeking health care at any health facility - with or without treatment - for any episode related to a SCD related illness? * Does the intervention lower all-cause death rate (at the end of 1, 2, 3 and 3.5 years of follow-up)? Researchers will compare the multifaceted intervention results with those of historical data (based on erratic SCD testing and treatment) from the region. Participants will undergo a SCD screening test using the Gazelle Multispectral platform and if positive they will undergo confirmatory testing with HemoTypeSC™. Participants with SCD will receive early comprehensive clinical interventions i.e. standard administration of antibacterial and antimalarial prophylaxis, vaccinations for pneumococcal and Haemophilus influenzae type b (Hib), hydroxyurea, parental education about the need for regular and, if necessary, urgent medical care.

Eligibility
Participation Requirements
Sex: All
Maximum Age: 6 months
Healthy Volunteers: f
View:

• Children aged 0 - 6 months old identified at selected health facilities within the study area

• Babies whose age plus the gestation period reaches 37 weeks or more

• Children who did not receive a blood transfusion within the past 90 days

• Children whose parents or guardians have consented to participate in the study by signing a consent form

Contact Information
Primary
Acellam Charles Abongomera, MD, MPH, PhD
charles.abongomera@swisstph.ch
+41612848629
Backup
Benjamin Koudou, PhD
guibehi.koudou@csrs.ci
+2250777205263
Time Frame
Start Date: 2026-07-27
Estimated Completion Date: 2029-12
Participants
Target number of participants: 120
Treatments
Experimental: Gazelle-Multispectral for newborn sickle cell disease screening; and early clinical interventions
A novel multifaceted intervention composed of: 1) integration of Gazelle-Multispectral point of care testing (POCT) for newborn sickle cell disease (SCD) screening; and 2) initiation of early comprehensive clinical interventions i.e. standard administration of antibacterial and antimalarial prophylaxis, vaccinations for pneumococcal and Haemophilus influenzae type b (Hib), hydroxyurea and parental education about SCD medical care.
Sponsors
Collaborators: Novartis Pharma AG, Switzerland, Centre Suisse de Recherches Scientifiques en Cote d'Ivoire
Leads: Swiss Tropical & Public Health Institute

This content was sourced from clinicaltrials.gov